WVE Wave Life Sciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1631574 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-72.6%
TTM EPS YoY-64.6%
Revenue 3-yr CAGR-6.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-320.9%
Net margin-296.9%
FCF margin-293.8%
EBITDA margin-316.1%
Returns
ROE-80.0%
ROA-56.2%
ROIC (approx.)-270.5%
Asset turnover0.19x
Leverage & solvency
Liabilities / assets20.9%
Debt / equity0.00x
Current ratio8.38x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.98x
Accruals ratio-0.9%
Payout ratio—
Capex / revenue1.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $42.73M | $108.30M |
| R&D expense | $182.78M | $159.68M |
| SG&A expense | $75.33M | $59.02M |
| Operating income | -$215.38M | -$110.40M |
| Pretax income | -$204.38M | -$97.01M |
| Income tax | $0 | $0 |
| Net income | -$204.38M | -$97.01M |
| EBITDA | -$211.94M | -$106.51M |
| EPS (basic) | -1.21 | -0.70 |
| EPS (diluted) | -1.21 | -0.70 |
| Weighted avg. shares (diluted) | 168.65M | 138.28M |
| Balance sheet | ||
| Cash & equivalents | $602.07M | $302.08M |
| Short-term investments | $0 | — |
| Receivables | $1.28M | $1.42M |
| Current assets | $614.81M | $320.39M |
| PP&E, net | $7.41M | $10.13M |
| Total assets | $638.50M | $352.21M |
| Current liabilities | $95.06M | $110.95M |
| Total liabilities | $112.27M | $134.82M |
| Shareholders' equity | $518.36M | $209.51M |
| Shares outstanding | 0 | 153.04M |
| Cash flow statement | ||
| Operating cash flow | -$187.49M | -$151.03M |
| Capital expenditure | $718,000 | $938,000 |
| Free cash flow | -$188.21M | -$151.96M |
| Investing cash flow | -$718,000 | -$938,000 |
| Financing cash flow | $488.24M | $253.89M |
| Depreciation & amortization | $3.44M | $3.90M |
| Stock-based compensation | $24.97M | $13.14M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.